Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

S. Kılıçkap · SciRah

Researcher profile · Semantic Scholar

S. Kılıçkap

Share profile

S. Kılıçkap — researcher profile on SciRah

h-index: 31
Works: 334
Citations: 4,708

Most-cited papers

Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial.
A. Sezer, S. Kılıçkap, M. Gümüş, I. Bondarenko +23 more
2021The Lancet591 citations
Semantic Scholar
The Association between the Pan-Immune-Inflammation Value and Cancer Prognosis: A Systematic Review and Meta-Analysis
D. Guven, T. K. Şahin, E. Erul, S. Kılıçkap +2 more
2022Cancers209 citations Open access
Semantic Scholar
Immune checkpoint inhibitor-related hearing loss: a systematic review and analysis of individual patient data
D. Guven, E. Erul, Yunus Kaygusuz, Baran Akagunduz +3 more
2023Supportive Care in Cancer159 citations
Semantic Scholar
First-line cemiplimab monotherapy and continued cemiplimab beyond progression plus chemotherapy for advanced non-small-cell lung cancer with PD-L1 50% or more (EMPOWER-Lung 1): 35-month follow-up from a mutlicentre, open-label, randomised, phase 3 trial.
M. Özgüroğlu, S. Kılıçkap, A. Sezer, M. Gümüş +20 more
2023The Lancet Oncology79 citations
Semantic Scholar
A global phase 3 study of serplulimab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (ASTRUM-004).
Cai-Cun Zhou, Yanping Hu, E. Arkania, S. Kılıçkap +22 more
2023Cancer Cell74 citations Open access
Semantic Scholar
Prevalence of EGFR Mutations in Patients With Resected Stage I-III NSCLC: Results From the EARLY-EGFR Study.
R. Soo, T. Reungwetwattana, H. Perroud, U. Batra +6 more
2024Journal of Thoracic Oncology56 citations Open access
Semantic Scholar
Newly diagnosed cancer and the COVID-19 pandemic: tumour stage migration and higher early mortality
D. Guven, T. K. Şahin, H. Yıldırım, E. Cesmeci +12 more
2021BMJ Supportive & Palliative Care44 citations Open access
Semantic Scholar
Central Nervous System Outcomes of Lazertinib Versus Gefitinib in EGFR-Mutated Advanced NSCLC: A LASER301 Subset Analysis.
Ross A. Soo, B. Cho, Joo-Hang Kim, Myung-Ju Ahn +19 more
2023Journal of Thoracic Oncology34 citations Open access
Semantic Scholar
Entrectinib in ROS1-positive advanced non-small cell lung cancer: the phase 2/3 BFAST trial
S. Peters, S. Gadgeel, T. Mok, E. Nadal +17 more
2024Nature Medicine32 citations Open access
Semantic Scholar
The relationship between pan-immune-inflammation value and survival outcomes in patients with metastatic renal cell carcinoma treated with nivolumab in the second line and beyond: a Turkish oncology group kidney cancer consortium (TKCC) study
E. Yekedüz, D. Tural, İ. Ertürk, S. Karakaya +12 more
2022Journal of Cancer Research and Clinical Oncology32 citations Open access
Semantic Scholar
The Association between Early Changes in Neutrophil-Lymphocyte Ratio and Survival in Patients Treated with Immunotherapy
D. Guven, T. K. Şahin, E. Erul, I. Cakir +7 more
2022Journal of Clinical Medicine31 citations Open access
Semantic Scholar
Antibody Responses to COVID-19 Vaccination in Cancer: A Systematic Review
D. Guven, T. K. Şahin, S. Kılıçkap, F. Uçkun
2021Frontiers in Oncology26 citations Open access
Semantic Scholar
Prognostic factors in patients with metastatic urothelial carcinoma who have treated with Atezolizumab
D. Tural, Ö. Ölmez, A. Sümbül, N. Ozhan +33 more
2021International Journal of Clinical Oncology20 citations
Semantic Scholar
The relationship between systemic immune inflammation index and survival in patients with metastatic renal cell carcinomatreated withtyrosine kinase inhibitors
K. B. Yücel, E. Yekedüz, S. Karakaya, D. Tural +15 more
2022Scientific Reports19 citations Open access
Semantic Scholar
Clinical outcomes of cyclin-dependent kinase 4–6 (CDK 4–6) inhibitors in patients with male breast cancer: A multicenter study
H. Yıldırım, E. Mutlu, E. Chalabiyev, M. Özen +20 more
2022Breast17 citations Open access
Semantic Scholar
Impact of pharmacist-led educational intervention on pneumococcal vaccination rates in cancer patients: a randomized controlled study
Nesligul Ozdemir, B. Aktaş, A. Gulmez, A. Inkaya +3 more
2023Supportive Care in Cancer16 citations Open access
Semantic Scholar
Patient‐reported outcomes with cemiplimab monotherapy for first‐line treatment of advanced non–small cell lung cancer with PD‐L1 of ≥50%: The EMPOWER‐Lung 1 study
M. Gümüş, Chieh-I Chen, C. Ivanescu, S. Kılıçkap +16 more
2022Cancer16 citations Open access
Semantic Scholar
Understanding of Clinical Trials Among Patients With Cancer and Their Relatives
Pınar Kubilay Tolunay, C. Erol, S. Kahraman, Seher Yıldız Tacar +9 more
2025JAMA Network Open14 citations Open access
Semantic Scholar
Lung Cancer in Turkey.
A. Cangir, P. Yumuk, S. Sak, S. Akyürek +16 more
2022Journal of Thoracic Oncology14 citations Open access
Semantic Scholar
The burden of polypharmacy and drug–drug interactions in older cancer patients treated with immunotherapy
D. Guven, Gozde Kavgacı, O. Aktepe, H. Yıldırım +5 more
2021Journal of Oncology Pharmacy Practice14 citations
Semantic Scholar
Treatment outcomes and prognostic factors in patients with driver mutant non-small cell lung cancer and de novo brain metastases
S. Kahraman, S. Karakaya, Muhammed Ali Kaplan, S. Goksu +43 more
2024Scientific Reports13 citations Open access
Semantic Scholar
Atezolizumab combined with chemotherapy in the first-line treatment of extensive-stage small cell lung cancer: a real-life data of the Turkish Oncology Group
Mustafa Gürbüz, Yasin Kutlu, E. Akkuş, E. Köksoy +35 more
2022Journal of Cancer Research and Clinical Oncology13 citations Open access
Semantic Scholar
Lower prognostic nutritional index is associated with poorer survival in patients receiving ımmune-checkpoint ınhibitors.
D. Guven, O. Aktepe, H. Taban, B. Aktaş +9 more
2021Biomarkers in Medicine10 citations
Semantic Scholar
The efficacy of palbociclib and ribociclib in the first-line treatment of metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer in male patients: a Turkish oncology group (TOG) study
H. Yıldırım, Yasin Kutlu, Emel Mutlu, M. Aykan +30 more
2024International Journal of Clinical Oncology9 citations
Semantic Scholar
Safety of lorlatinib in ALK-positive non-small-cell lung cancer and management of central nervous system adverse events.
S. Kılıçkap, Sertaç Ak, Oldac U Dursun, M. A. Şendur +2 more
2023Future Oncology9 citations Open access
Semantic Scholar
The Efficacy and Safety of Neoadjuvant Immunotherapy in Patients with Non-Small Cell Lung Cancer
D. Guven, T. Şahin, S. Kılıçkap
2023Cancers9 citations Open access
Semantic Scholar
Efficacy of Capecitabine and Temozolomide Regimen in Neuroendocrine Tumors: Data From the Turkish Oncology Group
Çağlar Ünal, A. Azizy, Senem Karabulut, D. Taştekin +60 more
2023The Oncologist9 citations Open access
Semantic Scholar
Blood Based Biomarkers as Predictive Factors for Hyperprogressive Disease
H. Yıldırım, D. Guven, O. Aktepe, H. Taban +6 more
2022Journal of Clinical Medicine9 citations Open access
Semantic Scholar
The association between albumin-globulin ratio (AGR) and survival in patients treated with immune checkpoint inhibitors
D. Guven, O. Aktepe, M. Aksun, T. K. Şahin +12 more
2021Cancer Biomarkers9 citations Open access
Semantic Scholar
Impact of opioid analgesics on survival in cancer patients receiving immune checkpoint inhibitors
Gozde Kavgacı, D. Guven, Yunus Kaygusuz, Ece Karaca +5 more
2024Supportive Care in Cancer8 citations Open access
Semantic Scholar
External Validation of a Novel Risk Model in Patients With Favorable Risk Renal Cell Carcinoma Defined by International Metastatic Renal Cell Carcinoma Database Consortium (IMDC): Results From the Turkish Oncology Group Kidney Cancer Consortium (TKCC) Database.
E. Yekedüz, S. Karakaya, İ. Ertürk, D. Tural +17 more
2022Clinical Genitourinary Cancer8 citations
Semantic Scholar
The Effectiveness of Adjuvant PD-1 Inhibitors in Patients With Surgically Resected Stage III/IV Acral Melanoma
H. Arak, S. Erkılıç, Ş. Yaslıkaya, Eda Eylemer Mocan +19 more
2024Journal of immunotherapy7 citations Open access
Semantic Scholar
The benefit of treatment beyond progression with immune checkpoint inhibitors: a multi-center retrospective cohort study
D. Guven, E. Yekeduz, E. Erul, S. C. Yazgan +7 more
2022Journal of Cancer Research and Clinical Oncology7 citations Open access
Semantic Scholar
Nivolumab in metastatic renal cell carcinoma: results from the Turkish Oncology Group Kidney Cancer Consortium database.
E. Yekedüz, İ. Ertürk, D. Tural, N. Karadurmuş +17 more
2021Future Oncology7 citations
Semantic Scholar
Trastuzumab ± Capecitabine Maintenance After the First-Line Treatment of HER2-Positive Advanced Gastric Cancer: Retrospective Observational Real-Life Data of Turkish Oncology Group
Mustafa Gürbüz, E. Akkuş, A. Sakin, S. Urvay +21 more
2021Journal of Gastrointestinal Cancer7 citations
Semantic Scholar
Cemiplimab monotherapy as first-line (1L) treatment of patients with brain metastases from advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) ≥ 50%: EMPOWER-Lung 1 subgroup analysis.
M. Ozguroglu, A. Sezer, S. Kılıçkap, M. Gumus +16 more
20217 citations
Semantic Scholar
Prognostic Significance of the Advanced Lung Cancer Inflammation Index in Metastatic Small Cell Lung Cancer: A Retrospective Analysis of 96 Patients
Muslih Ürün, Gürkan Güner, Yasin Sezgin, E. Uysal +2 more
2024Medical Science Monitor6 citations Open access
Semantic Scholar
Immunogenicity of two doses of inactive COVID‐19 vaccine and third booster dose mRNA vaccine in patients with cancer receiving active systemic therapy
D. Guven, Fatma Gul Gulbahce Incesu, H. Yıldırım, E. Erul +11 more
2022International Journal of Cancer6 citations Open access
Semantic Scholar
The incidence and risk factors for acute kidney injury in patients treated with immune checkpoint inhibitors
D. Guven, D. A. Ozbek, T. K. Şahin, Gozde Kavgacı +12 more
2022Anti-Cancer Drugs6 citations
Semantic Scholar
Response to first-line chemotherapy regimen is associated with efficacy of ımmune checkpoint blockade therapies in patients with metastatic urothelial carcinoma
D. Tural, F. Selçukbiricik, Ö. Ölmez, A. Sümbül +4 more
2021International Journal of Clinical Oncology6 citations Open access
Semantic Scholar
Efficacy of Immunotherapy Versus Chemotherapy in Advanced Pleural Mesothelioma: A Turkish Oncology Group (TOG) Study
Z. Kalkan, S. Ebinç, M. Arcagok, A. Bilici +10 more
2025Medicina5 citations Open access
Semantic Scholar
The percentage of ALK-positive cells and the efficacy of first-line alectinib in advanced non-small cell lung cancer: is it a novel factor for stratification? (Turkish Oncology Group Study)
M. Hızal, B. Bilgin, N. Paksoy, M. Atcı +34 more
2022Journal of Cancer Research and Clinical Oncology5 citations Open access
Semantic Scholar
Mean Platelet Volume to Lymphocyte Ratio: A New Biomarker Predicting Response in Patients with Solid Tumors Treated with Nivolumab
H. Yıldırım, Fatih Kuş, D. Guven, Ece Karaca +6 more
2023Journal of Immunotherapy and Precision Oncology4 citations Open access
Semantic Scholar
Clinical outcomes of concomitant use of proton pump inhibitors and regorafenib in patients with metastatic colorectal cancer: a multicenter study
E. Yekedüz, M. Özbay, Dilek Çağlayan, Atila Yıldırım +13 more
2022European Journal of Clinical Pharmacology4 citations Open access
Semantic Scholar
Efficacy/safety of entrectinib in patients (pts) with ROS1-positive (ROS1+) advanced/metastatic NSCLC from the Blood First Assay Screening Trial (BFAST).
Solange Peters, S. Gadgeel, T. Mok, E. Nadal +15 more
2022Journal of Clinical Oncology4 citations
Semantic Scholar
Five-Year Outcome and Safety in Patients Treated With Immune Checkpoint Blockade Therapies for Urothelial Carcinoma: Experience From Real-World Clinical Practice.
D. Tural, Ç. Arslan, F. Selçukbiricik, O. F. Olmez +6 more
2022Clinical Genitourinary Cancer4 citations
Semantic Scholar
Pazopanib-induced chylothorax in a patient with renal cell carcinoma.
B. Koylu, F. Tekin, B. Aktaş, S. Kılıçkap +1 more
2021Anti-Cancer Drugs4 citations
Semantic Scholar
Real-World Outcomes in BRAF-Mutant Non-small Cell Lung Cancer: A Multicenter Analysis From the Turkish Oncology Group.
T. Telli, A. Tatlı, Özkan Alan, Gül Keskin +32 more
2025Clinical Lung Cancer3 citations
Semantic Scholar
Circulating tumor DNA (ctDNA) dynamics and survival outcomes in patients (pts) with advanced non-small cell lung cancer (aNSCLC) and high (>50%) programmed cell death-ligand 1 (PD-L1) expression, randomized to cemiplimab (cemi) vs chemotherapy (chemo).
N. Vokes, D. Gandara, A. Sezer, S. Kılıçkap +16 more
2023Journal of Clinical Oncology3 citations
Semantic Scholar
Consensus Recommendations for the Diagnosis, Biomarker Testing, and Clinical Management of Advanced or Metastatic Non-small Cell Lung Cancer With Mesenchymal-Epithelial Transition Exon 14 Skipping Mutations in the Middle East, Africa, and Russia
M. Mahrous, Abdalla Omar Jebriel, Ahmed Allehebi, A. Shafik +11 more
2023Cureus3 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

H. Yıldırım×12
Invite
H. Yıldırım — researcher profile on SciRah
S. Aksoy×11
Invite
S. Aksoy — researcher profile on SciRah
Ş. Yalçın×11
Invite
Ş. Yalçın — researcher profile on SciRah
M. Şendur×11
Invite
M. Şendur — researcher profile on SciRah

×11

Invite

M. Erman — researcher profile on SciRah

N. Karadurmuş×10

Invite

N. Karadurmuş — researcher profile on SciRah

Invite

I. Çiçin — researcher profile on SciRah

Invite

D. Guven — researcher profile on SciRah

T. K. Şahin×9

Invite

T. K. Şahin — researcher profile on SciRah

Invite

Y. Ürün — researcher profile on SciRah

Invite

D. Tural — researcher profile on SciRah

Invite

D. Guven — researcher profile on SciRah